Important note
This AI stock analysis for ProPhase Labs is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!
ProPhase Labs - AI Stock Analysis
Analysis generated March 25, 2025
ProPhase Labs is a specialty healthcare company engaged in the research, development, manufacturing, and marketing of products that aid in healthcare maintenance and improvement. The company's portfolio ranges from clinical diagnostic services to over-the-counter remedies. The name ProPhase is synonymous with innovation in healthcare solutions, striving to meet the ongoing needs of consumers and healthcare partners alike.
Fundamental Analysis
In the last quarter, ProPhase Labs reported revenue of $3.1 million. This marks a 27.16% increase compared to the previous quarter, signaling positive short-term growth. However, it's important to note that this figure represents a 61.11% decline compared to the same quarter last year, raising questions about long-term sustainability.
The company's net income for the last quarter was $6.6 million, which is a 7.05% decrease from the previous quarter. More alarming is the year-over-year decline, where net income decreased by 28.13%. This trend could indicate potential issues in cost management or market conditions affecting profitability.
EBITDA for the last quarter stood at $7 million, reflecting a modest increase of 1.25% from the previous quarter. However, compared to the same quarter last year, EBITDA saw a drastic decline of 76.54%, which may point to significant changes in operating efficiencies or rising costs.
Technical Analysis
Today, ProPhase Labs' stock price is $0.53. This is an 8.16% increase compared to a month ago, which points to a positive short-term trend. However, over the past year, the stock has seen a significant drop of 91.57%. This discrepancy in short-term and long-term performance suggests volatility and potentially worrisome long-term fundamentals.
The Simple Moving Average over the past 10 days (SMA10) is $0.39, an increase from the previous SMA10 of $0.37. This suggests an upward trend in the stock's price movement. However, the Relative Strength Index (RSI) is 45, indicating a neutral condition. This balance in RSI suggests neither strong buying nor selling pressure in the market.
Alternative Data Analysis
Looking into alternative data sources, job postings and employee sentiment offer insights into internal company health. ProPhase Labs has about 2,000 visitors to their webpage, with no significant changes over recent months. This stability in web traffic might indicate a consistent level of consumer interest.
Finally, the AltIndex AI score, which predicts a company’s stock price based on a combination of fundamental, technical, and alternative data analysis, gives ProPhase Labs a score of 44. This suggests a 'hold' signal according to the AI-based model, reflecting balanced market expectations.
Conclusion
In conclusion, ProPhase Labs presents a mixed bag for investors. On the one hand, the recent revenue growth and a bullish short-term trend are positive signs. However, substantial declines in year-over-year revenue, net income, and EBITDA are concerning. The RSI and SMA10 data indicate potential upward movement, but the stock's significant long-term decline cannot be ignored.
Ultimately, ProPhase Labs offers an investment prospect with both short-term opportunities and long-term risks. Given the AltIndex AI score of 44 and an aggregate review of all data, maintaining a 'hold' position seems prudent. Investors might prefer to wait for more definitive trends before making further investment decisions.
Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.
